Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Nivolumab is a key immunotherapy for advanced non-small cell lung cancer (NSCLC).
• Vitamin D (VD) influences drug metabolism and immune function, relevant to NSCLC.
• The relationship between VD and nivolumab pharmacokinetics is previously unstudied.

Purpose of the Study:

• To investigate the association between plasma Vitamin D levels (25-hydroxyVD and 1,25-VD) and nivolumab concentrations.
• To evaluate the impact of VD-pathway gene polymorphisms on nivolumab levels and anti-nivolumab antibodies.
• To identify potential VD-related predictors of nivolumab concentration and treatment response in NSCLC.

Main Methods:

• Quantification of plasma 25-hydroxyVD, 1,25-VD, and nivolumab using ELISA.
• Detection of anti-nivolumab antibodies.
• Genotyping of VD-pathway-associated single nucleotide polymorphisms (SNPs) via real-time PCR.
• Analysis of 45 NSCLC patients at baseline and multiple time points during therapy.

Main Results:

• Median nivolumab concentrations increased over 60 days of therapy.
• No anti-nivolumab antibodies were detected.
• Significant correlations were found between nivolumab concentrations and 25-VD levels.
• VD-pathway gene SNPs influenced nivolumab concentrations.
• The VDBP AC/CC genotype combined with low baseline 25-VD (<10 ng/mL) predicted nivolumab levels <18.7 ug/mL at 15 days, associated with tumor progression.

Conclusions:

• This study is the first to demonstrate that Vitamin D markers predict nivolumab concentrations in NSCLC patients.
• Baseline 25-VD levels and VDBP genotype are potential indicators of nivolumab pharmacokinetics.
• These findings highlight the role of VD in nivolumab therapy and suggest potential for personalized treatment strategies.